Soluble IL-7Rα (sCD127) inhibits IL-7 activity and is increased in HIV infection

Journal of Immunology

Volumn 184, Issue 9, 2010, Pages 4679-4687

  Crawley, Angela M ^a,b   Faucher, Sylvie ^c   Angel, Jonathan B ^a,b,d  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^d UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 7; INTERLEUKIN 7 RECEPTOR ALPHA; PROTEIN BCL 2; PROTEIN KINASE B; STAT5 PROTEIN; IL7 PROTEIN, HUMAN; INTERLEUKIN 7 RECEPTOR; INTERLEUKIN 7 RECEPTOR, ALPHA CHAIN; INTERLEUKIN-7 RECEPTOR, ALPHA CHAIN;

ARTICLE; BIOLOGICAL ACTIVITY; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CONTROL GROUP; CONTROLLED STUDY; DRUG ACTIVITY; DRUG INHIBITION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PATHOGENESIS; PLASMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; BIOSYNTHESIS; BLOOD; CELL CULTURE; DRUG ANTAGONISM; IMMUNOLOGY; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY; SIGNAL TRANSDUCTION; SOLUBILITY; UPREGULATION;

CELLS, CULTURED; HIV INFECTIONS; HUMANS; INTERLEUKIN-7; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, INTERLEUKIN-7; SIGNAL TRANSDUCTION; SOLUBILITY; STAT5 TRANSCRIPTION FACTOR; UP-REGULATION;

EID: 77954491956     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0903758     Document Type: Article

References (53)

1. Booth, D. R., A. T. Arthur, S. M. Teutsch, C. Bye, J. Rubio, P. J. Armati, J. D. Pollard, R. N. Heard, and G. J. Stewart; Southern MS Genetics Consortium. 2005. Gene expression and genotyping studies implicate the interleukin 7 receptor in the pathogenesis of primary progressive multiple sclerosis. J. Mol. Med. 83: 822-830.
2. Korte, A., J. Köchling, L. Badiali, C. Eckert, J. Andreae, W. Geilen, C. Kebelmann-Betzing, T. Taube, S. Wu, G. Henze, and K. Seeger. 2000. Expression analysis and characterization of alternatively spliced transcripts of human IL-7Ralpha chain encoding two truncated receptor proteins in relapsed childhood all. Cytokine 12: 1597-1608.
3. Carini, C., M. F. McLane, K. H. Mayer, and M. Essex. 1994. Dysregulation of interleukin-7 receptor may generate loss of cytotoxic T cell response in human immunodeficiency virus type 1 infection. Eur. J. Immunol. 24: 2927-2934.
4. Heaney, M. L., and D. W. Golde. 1998. Soluble receptors in human disease. J. Leukoc. Biol. 64: 135-146.
5. Fernandez-Botran, R., F. A. Crespo, and X. Sun. 2002. Soluble cytokine receptors in biological therapy. Expert Opin. Biol. Ther. 2: 585-605.
6. Viviani, S., E. Camerini, V. Bonfante, A. Santoro, M. Balzarotti, M. Fornier, L. Devizzi, P. Verderio, P. Valagussa, and G. Bonadonna. 1998. Soluble interleukin-2 receptors (sIL-2R) in Hodgkin's disease: outcome and clinical implications. Br. J. Cancer 77: 992-997.
7. Maier, L. M., C. E. Lowe, J. Cooper, K. Downes, D. E. Anderson, C. Severson, P. M. Clark, B. Healy, N. Walker, C. Aubin, et al, and International Multiple Sclerosis Genetics Consortium. 2009. IL2RA genetic heterogeneity in multiple sclerosis and type 1 diabetes susceptibility and soluble interleukin-2 receptor production. PLoS Genet. 5: e1000322.
8. Selinsky, C. L., and M. D. Howell. 2000. Soluble tumor necrosis factor receptor type I enhances tumor development and persistence in vivo. Cell. Immunol. 200: 81-87.
9. Rose-John, S., J. Scheller, G. Elson, and S. A. Jones. 2006. Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer. J. Leukoc. Biol. 80: 227-236.
10. Stoklasek,T.A., K. S. Schluns, and L. Lefrançois. 2006.Combined IL-15/IL-15Ralpha immunotherapy maximizes IL-15 activity in vivo. J. Immunol. 177: 6072-6080.
11. Mortier, E., A. Quéméner, P. Vusio, I. Lorenzen, Y. Boublik, J. Grötzinger, A. Plet, and Y. Jacques. 2006. Soluble interleukin-15 receptor alpha (IL-15R alpha)-sushi as a selective and potent agonist of IL-15 action through IL-15R beta/gamma. Hyperagonist IL-15 x IL-15R alpha fusion proteins. J. Biol. Chem. 281: 1612-1619.
12. Cameron, D. W., A. J. Japour, Y. Xu, A. Hsu, J. Mellors, C. Farthing, C. Cohen, D. Poretz, M. Markowitz, S. Follansbee, et al. 1999. Ritonavir and saquinavir combination therapy for the treatment of HIV infection. AIDS 13: 213-224.
13. Goodwin, R. G., D. Friend, S. F. Ziegler, R. Jerzy, B. A. Falk, S. Gimpel, D. Cosman, S. K. Dower, C. J. March, A. E. Namen, et al. 1990. Cloning of the human and murine interleukin-7 receptors: demonstration of a soluble form and homology to a new receptor superfamily. Cell 60: 941-951.
14. Lyons, A. B. 2000. Analysing cell division in vivo and in vitro using flow cytometric measurement of CFSE dye dilution. J. Immunol. Methods 243: 147-154.
15. Faucher, S., A. M. Crawley, W. Decker, A. Sherring, D. Bogdanovic, T. Ding, M. Bergeron, J. B. Angel, and P. Sandstrom. 2009. Development of a quantitative bead capture assay for soluble IL-7 receptor alpha in human plasma. PLoS One 4: e6690.
16. Wofford, J. A., H. L. Wieman, S. R. Jacobs, Y. Zhao, and J. C. Rathmell. 2008. IL-7 promotes Glut1 trafficking and glucose uptake via STAT5-mediated activation of Akt to support T-cell survival. Blood 111: 2101-2111.
17. Pandrau-Garcia, D., B. de Saint-Vis, S. Saeland, N. Renard, S. Ho, I. Moreau, J. Banchereau, and J. P. Galizzi. 1994. Growth inhibitory and agonistic signals of interleukin-7 (IL-7) can be mediated through the CDw127 IL-7 receptor. Blood 83: 3613-3619.
18. Swainson, L., S. Kinet, C. Mongellaz, M. Sourisseau, T. Henriques, and N. Taylor. 2007. IL-7-induced proliferation of recent thymic emigrants requires activation of the PI3K pathway. Blood 109: 1034-1042.
19. Armitage, R. J., A. E. Namen, H. M. Sassenfeld, and K. H. Grabstein. 1990. Regulation of human T cell proliferation by IL-7. J. Immunol. 144: 938-941.
20. Welch, P. A., A. E. Namen, R. G. Goodwin, R. Armitage, and M. D. Cooper. 1989. Human IL-7: a novel T cell growth factor. J. Immunol. 143: 3562-3567.
21. Vranjkovic, A., A. M. Crawley, K. Gee, A. Kumar, and J. B. Angel. 2007. IL-7 decreases IL-7 receptor alpha (CD127) expression and induces the shedding of CD127 by human CD8+ T cells. Int. Immunol. 19: 1329-1339.
22. Fry, T. J., E. Connick, J. Falloon, M. M. Lederman, D. J. Liewehr, J. Spritzler, S. M. Steinberg, L. V. Wood, R. Yarchoan, J. Zuckerman, et al. 2001. A potential role for interleukin-7 in T-cell homeostasis. Blood 97: 2983-2990.
23. Bolotin, E., G. Annett, R. Parkman, and K.Weinberg. 1999. Serum levels of IL-7 in bone marrow transplant recipients: relationship to clinical characteristics and lymphocyte count. Bone Marrow Transplant. 23: 783-788.
24. MacPherson, P. A., C. Fex, J. Sanchez-Dardon, N. Hawley-Foss, and J. B. Angel. 2001. Interleukin-7 receptor expression on CD8(+) T cells is reduced in HIV infection and partially restored with effective antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 28: 454-457.
25. Colle, J. H., J. L. Moreau, A. Fontanet, O. Lambotte, M. Joussemet, J. F. Delfraissy, and J. Thèze. 2006. CD127 expression and regulation are altered in the memory CD8 T cells of HIV-infected patients-reversal by highly active anti-retroviral therapy (HAART). Clin. Exp. Immunol. 143: 398-403.
26. Sasson, S. C., J. J. Zaunders, G. Zanetti, E. M. King, K. M. Merlin, D. E. Smith, K. K. Stanley, D. A. Cooper, and A. D. Kelleher. 2006. Increased plasma interleukin-7 level correlates with decreased CD127 and Increased CD132 extracellular expression on T cell subsets in patients with HIV-1 infection. J. Infect. Dis. 193: 505-514.
27. Koesters, S. A., J. B. Alimonti, C. Wachihi, L. Matu, O. Anzala, J. Kimani, J. E. Embree, F. A. Plummer, and K. R. Fowke. 2006. IL-7Ralpha expression on CD4+ T lymphocytes decreases with HIV disease progression and inversely correlates with immune activation. Eur. J. Immunol. 36: 336-344.
28. Boutboul, F., D. Puthier, V. Appay, O. Pellé, H. Ait-Mohand, B. Combadière, G. Carcelain, C. Katlama, S. L. Rowland-Jones, P. Debré, et al. 2005. Modulation of interleukin-7 receptor expression characterizes differentiation of CD8 T cells specific for HIV, EBV and CMV. AIDS 19: 1981-1986.
29. Golden-Mason, L., J. R. Burton, Jr., N. Castelblanco, J. Klarquist, S. Benlloch, C. Wang, and H. R. Rosen. 2006. Loss of IL-7 receptor alpha-chain (CD127) expression in acute HCV infection associated with viral persistence. Hepatology 44: 1098-1109.
30. Seki, Y., J. Yang, M. Okamoto, S. Tanaka, R. Goitsuka, M. A. Farrar, and M. Kubo. 2007. IL-7/STAT5 cytokine signaling pathway is essential but insufficient for maintenance of naive CD4 T cell survival in peripheral lymphoid organs. J. Immunol. 178: 262-270.
31. Sasson, S. C., J. J. Zaunders, and A. D. Kelleher. 2006. The IL-7/IL-7 receptor axis: understanding its central role in T-cell homeostasis and the challenges facing its utilization as a novel therapy. Curr. Drug Targets 7: 1571-1582.
32. Mortier, E., J. Bernard, A. Plet, and Y. Jacques. 2004. Natural, proteolytic release of a soluble form of human IL-15 receptor alpha-chain that behaves as a specific, high affinity IL-15 antagonist. J. Immunol. 173: 1681-1688.
33. Rubinstein, M. P., M. Kovar, J. F. Purton, J. H. Cho, O. Boyman, C. D. Surh, and J. Sprent. 2006. Converting IL-15 to a superagonist by binding to soluble IL-15Ralpha. Proc. Natl. Acad. Sci. U.S.A. 103: 9166-9171.
34. Clarke, D., O. Katoh, R. V. Gibbs, S. D. Griffiths, and M. Y. Gordon. 1995. Interaction of interleukin 7 (IL-7) with glycosaminoglycans and its biological relevance. Cytokine 7: 325-330.
35. Havlir, D. V., F. J. Torriani, R. D. Schrier, J. Y. Huang, M. M. Lederman, K. A. Chervenak, and W. H. Boom. 2001. Serum interleukin-6 (IL-6), IL-10, tumor necrosis factor (TNF) alpha, soluble type II TNF receptor, and transforming growth factor beta levels in human immunodeficiency virus type 1-infected individuals with Mycobacterium avium complex disease. J. Clin. Microbiol. 39: 298-303.
36. Stone, S. F., P. Price, N. M. Keane, R. J. Murray, and M. A. French. 2002. Levels of IL-6 and soluble IL-6 receptor are increased in HIV patients with a history of immune restoration disease after HAART. HIV Med. 3: 21-27.
37. Maier, L. M., D. E. Anderson, C. A. Severson, C. Baecher-Allan, B. Healy, D. V. Liu, K. D. Wittrup, P. L. De Jager, and D. A. Hafler. 2009. Soluble IL-2RA levels in multiple sclerosis subjects and the effect of soluble IL-2RA on immune responses. J. Immunol. 182: 1541-1547.
38. Levine, S. J. 2004. Mechanisms of soluble cytokine receptor generation. J. Immunol. 173: 5343-5348.
39. Rose, T., O. Lambotte, C. Pallier, J. F. Delfraissy, and J. H. Colle. 2009. Identification and biochemical characterization of human plasma soluble IL-7R: lower concentrations in HIV-1-infected patients. J. Immunol. 182: 7389-7397.
40. Blom-Potar, M. C., F. Bugault, O. Lambotte, J. F. Delfraissy, and J. Thèze. 2009. Soluble IL-7Ralpha (sCD127) and measurement of IL-7 in the plasma of HIV patients. J. Acquir. Immune Defic. Syndr. 51: 104-105.
41. Napolitano, L. A., R. M. Grant, S. G. Deeks, D. Schmidt, S. C. De Rosa, L. A. Herzenberg, B. G. Herndier, J. Andersson, and J. M. McCune. 2001. Increased production of IL-7 accompanies HIV-1-mediated T-cell depletion: implications for T-cell homeostasis. Nat. Med. 7: 73-79.
42. Darcissac, E. C., V. Vidal, X. De La Tribonniere, Y. Mouton, and G. M. Bahr. 2001. Variations in serum IL-7 and 90K/Mac-2 binding protein (Mac-2 BP) levels analysed in cohorts of HIV-1 patients and correlated with clinical changes following antiretroviral therapy. Clin. Exp. Immunol. 126: 287-294.
43. Chiappini, E., L. Galli, C. Azzari, and M. de Martino. 2003. Interleukin-7 and immunologic failure despite treatment with highly active antiretroviral therapy in children perinatally infected with HIV-1. J. Acquir. Immune Defic. Syndr. 33: 601-604.
44. Page, T. H., J. L. Willcocks, D. A. Taylor-Fishwick, and B. M. Foxwell. 1993. Characterization of a novel high affinity human IL-7 receptor. Expression on T cells and association with IL-7 driven proliferation. J. Immunol. 151: 4753-4763.
45. Boyman, O., C. Ramsey, D. M. Kim, J. Sprent, and C. D. Surh. 2008. IL-7/anti- IL-7 mAb complexes restore T cell development and induce homeostatic T Cell expansion without lymphopenia. J. Immunol. 180: 7265-7275.
46. Puel, A., S. F. Ziegler, R. H. Buckley, and W. J. Leonard. 1998. Defective IL7R expression in T(-)B(+)NK(+) severe combined immunodeficiency. Nat. Genet. 20: 394-397.
47. Lundmark, F., K. Duvefelt, E. Iacobaeus, I. Kockum, E.Wallström, M. Khademi, A. Oturai, L. P. Ryder, J. Saarela, H. F. Harbo, et al. 2007. Variation in interleukin 7 receptor alpha chain (IL7R) influences risk of multiple sclerosis. Nat. Genet. 39: 1108-1113.
48. Limou, S. C. C., H. Do, A. Vasilescu, T. Labib, I. Gut, J. D. Lelievre, Y. Levy, and J. F. Zagury. 2008. Identification of an IL-7RA risk allele for rapid progression to AIDS: results of a genomic IL-7/IL-7RA study in the GRIV cohort. 15th Conference on Retroviruses and Opportunistic Infections. February 2008. Boston, MA.
49. Mazzucchelli, R., and S. K. Durum. 2007. Interleukin-7 receptor expression: intelligent design. Nat. Rev. Immunol. 7: 144-154.
50. Sportès, C., F. T. Hakim, S. A. Memon, H. Zhang, K. S. Chua, M. R. Brown, T. A. Fleisher, M. C. Krumlauf, R. R. Babb, C. K. Chow, et al. 2008. Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets. J. Exp. Med. 205: 1701-1714.
51. Levy, Y., C. Lacabaratz, L.Weiss, J. P. Viard, C. Goujard, J. D. Lelièvre, F. Boué, J. M. Molina, C. Rouzioux, V. Avettand-Fénoêl, et al. 2009. Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment. J. Clin. Invest. 119: 997-1007.
52. Leone, A. R. M., A. Okoye, B. Assouline, M. Morre, F. Villinger, L. Picker, and D. Sodora. 2008. IL-7 immunotherapy and T cell homeostasis in SIV+ ART-treated macaques. 15th Conference on Retroviruses and Opportunistic Infections. February 2008. Boston, MA.
53. Sereti, I., R. M. Dunham, J. Spritzler, E. Aga, M. A. Proschan, K. Medvik, C. A. Battaglia, A. L. Landay, S. Pahwa, M. A. Fischl, et al, and ACTG 5214 Study Team. 2009. IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection. Blood 113: 6304-6314.